SV2018005663A - IMIDAZO COMPOUNDS [4,5-C] QUINOLIN-2-ONA AND ITS USE IN CANCER TREATMENT - Google Patents

IMIDAZO COMPOUNDS [4,5-C] QUINOLIN-2-ONA AND ITS USE IN CANCER TREATMENT

Info

Publication number
SV2018005663A
SV2018005663A SV2018005663A SV2018005663A SV2018005663A SV 2018005663 A SV2018005663 A SV 2018005663A SV 2018005663 A SV2018005663 A SV 2018005663A SV 2018005663 A SV2018005663 A SV 2018005663A SV 2018005663 A SV2018005663 A SV 2018005663A
Authority
SV
El Salvador
Prior art keywords
compounds
salts
quinolin
ona
descriptive memory
Prior art date
Application number
SV2018005663A
Other languages
Spanish (es)
Inventor
Kurt Gordon Pike
Bernard Christophe Barlaam
Andrew John Eatherton
Thomas Anthony Hunt
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SV2018005663A publication Critical patent/SV2018005663A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

LA MEMORIA DESCRIPTIVA SE REFIERE EN GENERAL A COMPUESTOS DE FÓRMULA (I): (VER FORMULA) Y SALES FARMACÉUTICAMENTE ACEPTABLES DE LOS MISMOS, DONDE X, R1, R2, R3, R4 Y R5 TIENEN CUALQUIERA DE LOS SIGNIFICADOS DEFINIDOS EN EL PRESENTE DOCUMENTO. LA MEMORIA DESCRIPTIVA TAMBIÉN SE REFIERE AL USO DE COMPUESTOS DE FÓRMULA (I) Y SALES DE ESTOS PARA TRATAR O PREVENIR UNA ENFERMEDAD MEDIADA POR ATM, INCLUIDO EL CÁNCER. ESTA MEMORIA DESCRIPTIVA SE REFIERE ADEMÁS A COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN COMPUESTOS DE TIPO IMIDAZO[4,5-C]QUINOLIN-2-ONA SUSTITUIDOS Y SALES FARMACÉUTICAMENTE ACEPTABLES DE ESTOS; KITS QUE COMPRENDEN TALES COMPUESTOS Y SALES; MÉTODOS DE PRODUCCIÓN DE TALES COMPUESTOS Y SALES; E INTERMEDIOS ÚTILES EN TAL PRODUCCIÓNTHE DESCRIPTIVE MEMORY REFERS IN GENERAL TO FORMULA COMPOUNDS (I): (SEE FORMULA) AND PHARMACEUTICALLY ACCEPTABLE SALTS OF THE SAME, WHERE X, R1, R2, R3, R4 AND R5 HAVE ANY OF THE MEANINGS DEFINED IN THE PRESENT DOCUMENTS. THE DESCRIPTIVE MEMORY ALSO REFERS TO THE USE OF FORMULA COMPOUNDS (I) AND SALTS OF THESE TO TREAT OR PREVENT AN ATM-DISEASE DISEASE, INCLUDING CANCER. THIS DESCRIPTIVE MEMORY FURTHER REFERRES TO PHARMACEUTICAL COMPOSITIONS THAT INCLUDE IMPOSED TYPE COMPOUNDS [4,5-C] QUINOLIN-2-ONA SUBSTITUTED AND PHARMACEUTICALLY ACCEPTABLE SALES OF THESE; KITS THAT INCLUDE SUCH COMPOUNDS AND SALTS; PRODUCTION METHODS OF SUCH COMPOUNDS AND SALTS; AND USEFUL INTERMEDIATES IN SUCH PRODUCTION

SV2018005663A 2015-11-03 2018-04-06 IMIDAZO COMPOUNDS [4,5-C] QUINOLIN-2-ONA AND ITS USE IN CANCER TREATMENT SV2018005663A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1519406.1A GB201519406D0 (en) 2015-11-03 2015-11-03 Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer

Publications (1)

Publication Number Publication Date
SV2018005663A true SV2018005663A (en) 2018-07-20

Family

ID=55130605

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2018005663A SV2018005663A (en) 2015-11-03 2018-04-06 IMIDAZO COMPOUNDS [4,5-C] QUINOLIN-2-ONA AND ITS USE IN CANCER TREATMENT

Country Status (20)

Country Link
US (1) US20180318287A1 (en)
EP (1) EP3371183A1 (en)
JP (1) JP2018536649A (en)
KR (1) KR20180070703A (en)
CN (1) CN108349971A (en)
AU (1) AU2016348546B2 (en)
BR (1) BR112018007772A2 (en)
CA (1) CA3002608A1 (en)
CL (1) CL2018001146A1 (en)
CO (1) CO2018003969A2 (en)
CR (1) CR20180307A (en)
GB (1) GB201519406D0 (en)
HK (2) HK1255598A1 (en)
IL (1) IL258818A (en)
MX (1) MX2018005445A (en)
PE (1) PE20181345A1 (en)
PH (1) PH12018500958A1 (en)
RU (1) RU2018120318A (en)
SV (1) SV2018005663A (en)
WO (1) WO2017076895A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201825465A (en) 2016-09-23 2018-07-16 美商基利科學股份有限公司 Phosphatidylinositol 3-kinase inhibitors
TW201813963A (en) 2016-09-23 2018-04-16 美商基利科學股份有限公司 Phosphatidylinositol 3-kinase inhibitors
TW201815787A (en) 2016-09-23 2018-05-01 美商基利科學股份有限公司 Phosphatidylinositol 3-kinase inhibitors
CN111344293A (en) 2017-09-20 2020-06-26 阿斯利康(瑞典)有限公司 1, 3-dihydroimidazo [4, 5-c ] cinnolin-2-one compounds and their use in the treatment of cancer
WO2019201283A1 (en) * 2018-04-20 2019-10-24 Xrad Therapeutics, Inc. Dual atm and dna-pk inhibitors for use in anti-tumor therapy
CN110386932A (en) * 2018-04-20 2019-10-29 艾科思莱德制药公司 For the dual ATM and DNA-PK inhibitor in antitumor therapy
WO2020052688A1 (en) 2018-09-14 2020-03-19 Suzhou Zanrong Pharma Limited 1-ISOPROPYL-3-METHYL-8- (PYRIDIN-3-YL) -1, 3-DIHYDRO-2H-IMIDAZO [4, 5-c] CINNOLIN-2-ONE AS SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE AND USES THEREOF
CA3114646C (en) * 2018-09-30 2022-03-08 Medshine Discovery Inc. Quinolino-pyrrolidin-2-one derivatives and application thereof
US20220204527A1 (en) * 2019-03-05 2022-06-30 Astrazeneca Ab Fused tricyclic compounds useful as anticancer agents
CN114746421A (en) * 2019-11-19 2022-07-12 南京明德新药研发有限公司 Substituted quinolinopyrrolones as ATM inhibitors and uses thereof
WO2021139814A1 (en) * 2020-01-09 2021-07-15 南京明德新药研发有限公司 Quinoline imidazole compound and application thereof
WO2021197339A1 (en) * 2020-03-30 2021-10-07 南京明德新药研发有限公司 Crystal form of quinopyrrolidine-2-one compound serving as atm inhibitor and use thereof
JP2023539715A (en) 2020-06-24 2023-09-19 アストラゼネカ ユーケー リミテッド Combination of antibody-drug conjugates and ATM inhibitors
EP4142710B1 (en) 2020-09-21 2024-01-31 Wei Zhong Substituted 1-(3,3-difluoropiperidin-4-yl)-imidazo[4,5-c] quinolin-2-one compounds with blood-brain barrier penetrable capability
EP3992191A1 (en) 2020-11-03 2022-05-04 Deutsches Krebsforschungszentrum Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors
WO2022128833A1 (en) 2020-12-15 2022-06-23 Merck Patent Gmbh Solid transition metal-ligand complexes
IL314381A (en) * 2022-01-26 2024-09-01 Chia Tai Tianqing Pharmaceutical Group Co Ltd Hydrazino group-containing compound
WO2023200427A1 (en) * 2022-04-11 2023-10-19 Wei Zhong Substituted 1-(3,3-difluoropiperidin-4-yl)-imidazo[4,5-c] quinolin-2-one derivative crystal form, salt crystal form, preparation method and application

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010139747A1 (en) * 2009-06-04 2010-12-09 Novartis Ag 1H-IMIDAZO[4, 5-c]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES
CN102372711B (en) * 2010-08-18 2014-09-17 山东轩竹医药科技有限公司 Imidazo quinoline PI3K and mTOR (mammalian target of rapamycin) dual inhibitor
CN102399218A (en) * 2010-09-16 2012-04-04 和记黄埔医药（上海）有限公司 Triheterocyclic compounds and their use as PI3K inhibitors
NO2714752T3 (en) * 2014-05-08 2018-04-21
EP3560924B1 (en) * 2015-04-02 2021-03-31 Merck Patent GmbH Imidazolonyl quinolines and their use as atm kinase inhibitors

Also Published As

Publication number Publication date
EP3371183A1 (en) 2018-09-12
RU2018120318A (en) 2019-12-05
HK1255598A1 (en) 2019-08-23
CN108349971A (en) 2018-07-31
GB201519406D0 (en) 2015-12-16
US20180318287A1 (en) 2018-11-08
WO2017076895A1 (en) 2017-05-11
RU2018120318A3 (en) 2019-12-24
KR20180070703A (en) 2018-06-26
AU2016348546A1 (en) 2018-06-14
CR20180307A (en) 2018-10-05
BR112018007772A2 (en) 2018-10-30
JP2018536649A (en) 2018-12-13
PH12018500958A1 (en) 2018-11-19
IL258818A (en) 2018-06-28
HK1257678A1 (en) 2019-10-25
CO2018003969A2 (en) 2018-07-10
CL2018001146A1 (en) 2018-09-04
CA3002608A1 (en) 2017-05-11
PE20181345A1 (en) 2018-08-22
MX2018005445A (en) 2018-08-14
AU2016348546B2 (en) 2019-05-02

Similar Documents

Publication Publication Date Title
SV2018005663A (en) IMIDAZO COMPOUNDS [4,5-C] QUINOLIN-2-ONA AND ITS USE IN CANCER TREATMENT
SV2018005680A (en) IMIDAZO COMPOUNDS [4,5-C] QUINOLIN-2-ONA AND ITS USE IN CANCER TREATMENT
SV2018005655A (en) "DERIVATIVES OF 8- [6- [3- (AMINO) PROPOXI] -3-PIRIDIL] 1-ISOPROPILIMIDAZO [4,5-C] QUINOLIN-2-ONA AS SELECTED MODULATORS OF THE MUTED TELANGIECTASIA ATAXIA KINASE (ATM) FOR THE TREATMENT OF CANCER "
CL2019001714A1 (en) Amino-triazolopyridine compounds and their use in the treatment of cancer.
UY36112A (en) IMIDAZO COMPOUNDS [4,5-C] QUINOLIN-2-ONA AND ITS USE TO TREAT CANCER
CO2017002998A2 (en) Tetrahydronaphthalene derivatives that inhibit mcl-1 protein
SV2018005687A (en) DIHYDROIMIDAZOPIRAZINONA DERIVATIVES USED IN CANCER TREATMENT
CO2017004525A2 (en) Ror-gamma inhibitory dihydropyrrolopyridines
AR108461A1 (en) IMIDAZO COMPOUNDS [4,5-C] QUINOLIN-2-ONA AND ITS USE IN CANCER TREATMENT
AR100431A1 (en) PIRIDINE PLADIENOLIDE COMPOUNDS AND METHODS OF USE
CL2019002527A1 (en) Deuterated imidazo [4,5-c] quinolin-2-one compounds and their use in the treatment of cancer.
NI201600176A (en) COMPOUNDS OF 1, 3, 4 - TIADIAZOLE AND THE USE OF THEM FOR THE TREATMENT OF CANCER.
CL2017000682A1 (en) Novel imidazopyridazine compounds and their use.
CO2018010951A2 (en) Cinnolin-4-amine compounds and their use in cancer treatment
PE20181450A1 (en) 1,3,4-THADIAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER